Survival benefit for bemarituzumab + chemo in 1L gastric cancer attenuates at final analysis September 9, 2025
ATG-022 Granted Breakthrough Therapy Designation for the Treatment of Gastric/GEJ Adenocarcinoma August 26, 2025
First Patient Dosed in Pivotal Ph 3 Trial of Cadonilimab for Perioperative Treatment of Resectable Gastric Cancer August 26, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and GEJ cancers July 29, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Presentation of positive Ph 1b data for givastomig, nivolumab, and mFOLFOX6 combo in 1L gastric cancer patients announced July 8, 2025
Ph 3 FORTITUDE-101 of 1L bemarituzumab plus chemotherapy (mFOLFOX6) in gastric cancer patients met primary endpoint of OS July 1, 2025
CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the 1L Treatment of Gastric/GEJ Cancer June 17, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis May 6, 2025
ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial March 11, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
ASCO GI 2025: Positive Updated Data from ASPEN-06 Ph 2 Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer presented January 28, 2025
ASCO GI 2025: Latest Ph 1/2 Data on ATN-022 in Advanced/Metastatic Gastric Cancer Including an ORR of 42.9% presented January 28, 2025
China’s NMPA Approves VYLOYTM (zolbetuximab) for 1L Treatment of Advanced Gastric or GEJ Adenocarcinoma January 7, 2025
TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ Cancers in Combination with Chemotherapy December 31, 2024
